Q1 Earnings Forecast for Longeveron Issued By HC Wainwright

Longeveron Inc. (NASDAQ:LGVN) – Analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Longeveron in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.37) per share for the quarter, up from their prior forecast of ($0.40). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.31) EPS.

A number of other research analysts have also commented on LGVN. Roth Mkm began coverage on shares of Longeveron in a research report on Friday, December 6th. They set a “buy” rating and a $10.00 price objective for the company. Roth Capital raised shares of Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th.

Longeveron Price Performance

Longeveron stock opened at $1.44 on Thursday. The firm has a market cap of $21.37 million, a price-to-earnings ratio of -0.23 and a beta of 0.37. Longeveron has a fifty-two week low of $0.77 and a fifty-two week high of $6.40. The firm has a fifty day moving average price of $1.64 and a two-hundred day moving average price of $1.89.

Institutional Trading of Longeveron

Several large investors have recently added to or reduced their stakes in LGVN. State Street Corp bought a new stake in Longeveron during the third quarter worth about $29,000. Northern Trust Corp acquired a new position in Longeveron in the fourth quarter valued at approximately $31,000. Jane Street Group LLC acquired a new position in Longeveron in the fourth quarter valued at approximately $35,000. Virtu Financial LLC acquired a new position in Longeveron in the fourth quarter valued at approximately $53,000. Finally, Geode Capital Management LLC lifted its holdings in Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares during the period. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.